GlassScriptPhysician profile
Pasindu Bharatha Samarasinghe
NPI 1598127003
$4,357.01
in general payments reported to CMS, 2019-2025
29 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.43 · 2020: $49.11 · 2021: $459 · 2022: $835 · 2023: $1,131 · 2024: $1,271 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,994.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $835.02 | 2022-2024 | Airsupra, Farxiga |
| Abbvie INC. | $510.47 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $417.82 | 2022-2024 | Arexvy, Shingrix |
| Amgen INC. | $271.26 | 2022-2025 | Repatha, Krystexxa |
| Medtronic, INC. | $266.85 | 2021-2023 | Closurefast, Interstim |
| Idorsia Pharmaceuticals US INC | $260.64 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $247.20 | 2021-2022 | |
| Novo Nordisk INC | $231.16 | 2020-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $181.59 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $136.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $136.48 | 2024 | Voquezna |
| Janssen Biotech, INC. | $122.09 | 2025 | Simponi Aria, Tremfya |
| Exact Sciences Corporation | $122.09 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $112.34 | 2021-2024 | |
| Alkermes, INC. | $98.43 | 2023 | Vivitrol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $92.60 | 2023 | Inspire |
| Myriad Women'S Health, INC. | $68.31 | 2023 | Myrisk |
| Abbott Laboratories | $37.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.14 | 2020 | |
| Astellas Pharma US INC | $21.02 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.69 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.68 | 2021 | |
| Amryt Pharma Holdings LTD | $18.54 | 2023 | Mycapssa |
| Verona Pharma, INC. | $17.78 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $17.04 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.27 | 2023 | Xifaxan |
| Endo Pharmaceuticals INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pasindu Samarasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.